Abstract:Current therapeutic options for hearing loss rely on hearing aids, ossiculoplasty or cochlear implants. These devices have limitations, particularly in noisy acoustic environments. Therefore, interest in exploring aetiological treatments to improve not only auditory perception but also the quality of life of those affected is increasing. Gene therapy is a promising aetiological treatment that can fully restore auditory function. The success of gene therapy relies on the efficient delivery of therapeutic genes or genetic modifications to the cells of the inner ear that are designed to repair or replace defective genes and restore normal hearing function. Two main strategies for gene therapy involve the use of recombinant viral vectors and nonviral delivery vehicles. Owing to their excellent diffusion properties and compatibility with sensory cells, recombinant viral vectors, particularly adeno-associated viruses (AAVs), have dominated gene therapy in the cochlea. However, recombinant viral vectors have several drawbacks, such as limited transgene size, immunogenicity (particularly in neonates), and potential need for repeat administration. Nonviral vectors, such as cationic lipids and polymeric nanoparticles, are potential attractive alternatives. Nonviral vectors have several advantages, including low immunogenicity and unlimited transgene size. Recent studies have demonstrated significant auditory recovery in vivo using nonviral vectors in murine models. However, nonviral vectors are not as efficient as viral vectors in transferring genetic material. An alternative to nanoparticles is the use of other methods, such as electroporation. The main advantage of electroporation is that it can be used in combination with cochlear implantation and can target surface cells, but this method has a risk of cell damage. The goal of this review is to provide valuable insights into the current state of research on nonviral vectors for inner ear gene therapy and propose the exploration of innovative and effective gene therapy strategies for the treatment of hearing loss.

Genome and base editing for genetic hearing loss

The Application of Genome Editing in Studying Hearing Loss.

Gene editing based hearing impairment research and therapeutics

Recent advances and future challenges in gene therapy for hearing loss

The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss

A Review of Application of Base Editing for the Treatment of Inner Ear Disorders

Genetic Hearing Loss and Gene Therapy

Template-independent genome editing in the <i>Pcdh15<SUP>av-3j</SUP></i> mouse, a model of human DFNB23 nonsyndromic deafness

Gene Therapy for Human Sensorineural Hearing Loss

Template-independent Genome Editing in the Pcdh15 Mouse, a Model of Human DFNB23 Nonsyndromic Deafness

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Gene therapy for deafness

Deafness: from genetic architecture to gene therapy

Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction

Gene editing in a Myo6 semi-dominant mouse model rescues auditory function

Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems

Milestones toward cochlear gene therapy for patients with hereditary hearing loss

Advances in Gene Therapy Hold Promise for Treating Hereditary Hearing Loss

Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success.